Sarcopenia Treatment Market to Experience 4.2% CAGR, Reaching US$ 4.63 Billion by 2034 | Fact.MR Report

Rockville, MD, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The world population has crossed 8 billion, with a significant number of elderly people suffering from sarcopenia. As per a new study by Fact.MR, the global sarcopenia treatment market is estimated at US$ 3.07 billion in 2024 and is projected to expand at a CAGR of 4.2% from 2024 to 2034.

The market is progressing as younger individuals increasingly recognize the signs of such conditions and pursue treatment. Treatment options include dietary and exercise therapies, often recommended by rheumatologists based on age and immune system. All of these factors are driving market growth as patients increasingly rely on these therapies.

Myostatin, vitamin D, angiotensin, and omega-3 supplements are favored by consumers for their ability to enhance strength recovery with minimal side effects, thus increasing demand for treatments. Rising personal healthcare expenses are projected to drive demand for sarcopenia treatment supplements.

• According to the National Health Expenditure Accounts (NHEA), healthcare spending in the United States grew by 4.3% in 2016, reaching US$ 3.3 trillion, or US$ 10,348 per person.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=10051

Key Takeaways from Market Study

• The global sarcopenia market is projected to reach US$ 4.63 billion by the end of 2034.
• The North American market is forecasted to expand at a 6% CAGR through 2034.
• In 2024, protein supplements are estimated to account for 5% of the market share.
• By 2034, Latin America is projected to hold 7% of the global market share.
• The market in Brazil is forecasted to expand at a CAGR of 1% from 2024 and 2034.

"Increasing prevalence of sarcopenia is necessitating early diagnosis and ...

Full story available on Benzinga.com